MG
RXDX

Michael Gelband’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Michael Gelband’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-58,070
Closed -$6.39M – 2229
2022
Q4 		$6.39M Buy
+58,070
New +$3.77M 0.09% 285

Other funds holding RXDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's RXDX Position: Q1 2023 in Review

Michael Gelband sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 58,070 shares — an estimated $6.39M sold.

Michael Gelband first reported a position in RXDX in Q4 2022 and held it in 1 quarter. The position peaked at $6.39M in Q4 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

  • Michael Gelband reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Michael Gelband sold 58,070 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $6.39M.
  • Michael Gelband first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Michael Gelband's Prometheus Biosciences, Inc. Common Stock position peaked at $6.39M in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.